[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 49 of about 49
1. Bullitt E, Zeng D, Gerig G, Aylward S, Joshi S, Smith JK, Lin W, Ewend MG: Vessel tortuosity and brain tumor malignancy: a blinded study. Acad Radiol; 2005 Oct;12(10):1232-40
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vessel tortuosity and brain tumor malignancy: a blinded study.
  • RATIONALE AND OBJECTIVES: Malignancy provokes regional changes to vessel shape.
  • Characteristic vessel tortuosity abnormalities appear early during tumor development, affect initially healthy vessels, spread beyond the confines of tumor margins, and do not simply mirror tissue perfusion.
  • MATERIALS AND METHODS: The regional vasculature of 34 healthy subjects was compared with the tumor-associated vasculature of 30 brain tumors before surgical resection.
  • Vessels were segmented from an MRA of each subject, a region of interest was defined in each tumor patient and was mapped to all healthy controls, and a statistical analysis of vessel shape measures was then performed over the region of interest.
  • Many difficult cases were included, such as pinpoint, hemorrhagic, and irradiated tumors, as were hypervascular benign tumors.
  • Tumors were identified as benign or malignant on the basis of histological evaluation.
  • RESULTS: A discriminant analysis performed at the study's conclusion successfully classified all but one of the 30 tumors as benign or malignant on the basis of vessel tortuosity.
  • CONCLUSIONS: Quantitative, statistical measures of vessel shape offer a new approach to the diagnosis and staging of disease.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acad Radiol. 2003 Dec;10(12):1341-8 [14697002.001]
  • [Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Neuroradiology. 2001 May;43(5):345-52 [11396737.001]
  • [Cites] Brain Tumor Pathol. 2000;17(3):111-20 [11310918.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Feb;14(1):31-6 [10850285.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):94-5 [10639502.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1284-91 [11948144.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] Med Image Anal. 2005 Feb;9(1):39-49 [15581811.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):577-84 [15560715.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Apr;105(4):795-805 [4308528.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]
  • (PMID = 16179200.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219-07; United States / NIBIB NIH HHS / EB / R01 EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NIBIB NIH HHS / EB / EB000219-07
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS53777; NLM/ PMC2517122
  •  go-up   go-down


2. Sladkevicius P, Jokubkiene L, Valentin L: Contribution of morphological assessment of the vessel tree by three-dimensional ultrasound to a correct diagnosis of malignancy in ovarian masses. Ultrasound Obstet Gynecol; 2007 Nov;30(6):874-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of morphological assessment of the vessel tree by three-dimensional ultrasound to a correct diagnosis of malignancy in ovarian masses.
  • OBJECTIVE: To determine whether subjective evaluation of the morphology of the vessel tree of ovarian tumors, as depicted by three-dimensional (3D) power Doppler ultrasound, can discriminate between benign and malignant ovarian tumors, and whether it improves characterization compared with using gray-scale ultrasound imaging alone.
  • Predetermined vessel characteristics, e.g. density of vessels, branching, caliber changes and tortuosity, were evaluated in 360 degrees rotating 3D images of the vessel tree of the tumor.
  • RESULTS: There were 77 benign tumors, six borderline tumors and 21 invasive malignancies.
  • All vascular features differed significantly between benign and malignant tumors.
  • Adding branching of vessels in the whole tumor to the gray-scale model yielded an AUC of 0.99 and resulted in all malignancies and an additional four benign tumors being correctly classified.
  • CONCLUSIONS: Subjective evaluation of the morphology of the vessel tree, as depicted by 3D power Doppler ultrasound, can be used to discriminate between benign and malignant ovarian tumors, but adds little to gray-scale ultrasound imaging in an ordinary population of tumors.
  • [MeSH-major] Ovarian Neoplasms / blood supply. Ovarian Neoplasms / ultrasonography
  • [MeSH-minor] Area Under Curve. Blood Vessels / ultrasonography. Diagnosis, Differential. Female. Humans. Imaging, Three-Dimensional. Middle Aged. Sensitivity and Specificity. Ultrasonography, Doppler

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943717.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


3. Fleischmann A, Waser B, Reubi JC: Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms. Cell Oncol; 2007;29(5):421-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms.
  • GRP-receptor positive vessels were present in the various classes of ovarian tumors; generally, malignant tumors had a higher incidence of GRP-receptor positive vessels compared to their benign counterparts.
  • The GRP-receptors were expressed in high density in the muscular vessel wall.
  • CONCLUSIONS: The large amounts of GRP-receptors in ovarian tumor vessels suggest a role in tumoral vasculature and possibly angiogenesis.
  • [MeSH-major] Neovascularization, Pathologic. Ovarian Neoplasms / blood supply. Receptors, Bombesin / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726264.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Bombesin
  • [Other-IDs] NLM/ PMC4618228
  •  go-up   go-down


Advertisement
4. Sawhney MS, Debold SM, Kratzke RA, Lederle FA, Nelson DB, Kelly RF: Central intranodal blood vessel: a new EUS sign described in mediastinal lymph nodes. Gastrointest Endosc; 2007 Apr;65(4):602-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central intranodal blood vessel: a new EUS sign described in mediastinal lymph nodes.
  • BACKGROUND: The vascular architecture of normal lymph nodes is composed of prominent centrally located blood vessels.
  • In malignant nodes, this pattern is distorted because of tumor infiltration and neovascularization.
  • OBJECTIVE: To determine whether EUS imaging of central intranodal blood vessels (CIV) can be used to differentiate benign from malignant subcarinal lymph nodes in lung cancer.
  • DESIGN: CIV was defined as a > or =1-mm-diameter tubular structure, with well-defined walls and blood flow.
  • RESULTS: Of 67 patients included in the retrospective analysis, CIV was noted in 17 of 35 patients with benign nodes (49%), compared with 5 of 32 patients with malignant nodes (16%) (P = .002).
  • In lymph nodes > or =1 cm, CIV was noted in 14 of 16 patients with benign nodes (88%), compared with 2 of 27 with malignant nodes (7%) (P < .001).
  • CONCLUSIONS: The absence of a central intranodal blood vessel was a strong and independent predictor of malignancy in lymph nodes of patients with lung cancer and can be used to select lymph nodes for FNA.
  • [MeSH-major] Endosonography / methods. Lung Neoplasms / pathology. Lymph Nodes / blood supply. Lymph Nodes / ultrasonography. Lymphatic Metastasis / ultrasonography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17383457.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Ai ZH, Zhang WX: [Expression of pin1 mRNA in the circulation of non-small cell lung cancer patients and influence of sequence of vessel ligation]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Dec;33(12):1132-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of pin1 mRNA in the circulation of non-small cell lung cancer patients and influence of sequence of vessel ligation].
  • Blood samples were collected just before and 7 days after the operation.
  • During the lobectomy, blood samples of the proximal part and distal part of the pulmonary vein when it was ligated were collected.
  • Another 10 patients with benign lung disease served as control subjects undergoing surgical resection, and 10 healthy persons served as negative controls.
  • All blood samples were subjected to real-time RT-PCR with pin1 mRNA as the marker.
  • RESULTS: Compared with the benign lung disease and healthy persons, pin1 mRNA in NSCLC was overexpressed (1.45 to approximately 29.86 vs.0.83 to approximately 1.26 vs 1, P<0.05).
  • Ligation of pulmonary vein before the ligation of the pulmonary artery may decrease the expression of pin1 mRNA in the circulation, which can prevent the release of tumor cells into the bloodstream.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141981.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NIMA-interacting peptidylprolyl isomerase; 0 / RNA, Messenger; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


6. Song TK, Harris EJ Jr, Raghavan S, Norton JA: Major blood vessel reconstruction during sarcoma surgery. Arch Surg; 2009 Sep;144(9):817-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Major blood vessel reconstruction during sarcoma surgery.
  • OBJECTIVE: To evaluate the outcomes of major vessel reconstruction as part of surgery to remove sarcomas.
  • PATIENTS: Fourteen patients (10 female) with retroperitoneal or extremity sarcomas and major blood vessel involvement who underwent surgery to remove the tumor and had blood vessel reconstruction between 2003 and 2008.
  • Thirteen tumors were malignant (7 high grade and 6 low grade) and 1, benign (leiomyoma).

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19797105.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Hannan FM, Athanasou NA, Teh J, Gibbons CL, Shine B, Thakker RV: Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1. Eur J Endocrinol; 2008 Feb;158(2):265-71
Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
  • Here, we demonstrate the roles of serum FGF23 and 1,25(OH)2D3, together with the lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), as biomarkers for OOM.
  • In addition, the demonstration of lymphatics in the PMTMCT helps to distinguish this tumour from most typical benign haemangiomas.
  • [MeSH-major] Antigens, CD44 / blood. Biomarkers, Tumor / blood. Fibroblast Growth Factors / blood. Hypophosphatemia / complications. Osteomalacia / diagnosis. Osteomalacia / etiology. Paraneoplastic Syndromes. Vitamin D / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Alkaline Phosphatase / blood. Biomarkers / blood. Bone Neoplasms / blood. Bone Neoplasms / diagnosis. Bone Neoplasms / surgery. Calcitriol / administration & dosage. Chondrosarcoma, Mesenchymal / blood. Chondrosarcoma, Mesenchymal / diagnosis. Chondrosarcoma, Mesenchymal / surgery. Endothelium, Vascular. Humans. Knee. Lymphatic Vessels. Male. Middle Aged. Phosphates / administration & dosage. Predictive Value of Tests

  • Genetic Alliance. consumer health - Oncogenic osteomalacia.
  • Genetic Alliance. consumer health - Osteomalacia.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18230836.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G84/6423; United Kingdom / Medical Research Council / / MRC/ G9825289
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Phosphates; 0 / dihydroxy-vitamin D3; 0 / fibroblast growth factor 23; 1406-16-2 / Vitamin D; 62031-54-3 / Fibroblast Growth Factors; EC 3.1.3.1 / Alkaline Phosphatase; FXC9231JVH / Calcitriol
  •  go-up   go-down


8. Colella G, Giudice A, Vicidomini A, Sperlongano P: Usefulness of the LigaSure vessel sealing system during superficial lobectomy of the parotid gland. Arch Otolaryngol Head Neck Surg; 2005 May;131(5):413-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of the LigaSure vessel sealing system during superficial lobectomy of the parotid gland.
  • DESIGN: Prospective study of the surgical procedures in the LigaSure Vessel Sealing System and comparison with a conventionally treated control group.
  • Patients Thirty-five patients with a parotid gland benign tumor were randomly allocated to 2 superficial lobe parotidectomy groups: 17 using the LigaSure procedure (group A) and 18 using the conventional method (group B).
  • With the whole LigaSure Vessel Sealing System, we experienced the usefulness of the LigaSure Precise instrument in superficial lobectomy of the parotid gland.
  • RESULTS: No statistically significant differences were noted between the 2 groups in mean age, tumor diameter, length of hospital stay, time to return to work, or number of adverse events during or after surgery.
  • [MeSH-minor] Adult. Aged. Blood Loss, Surgical / prevention & control. Female. Hemostasis, Surgical / instrumentation. Humans. Length of Stay / statistics & numerical data. Ligation / instrumentation. Male. Middle Aged. Pain Measurement. Postoperative Complications. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897420.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


9. Ding S, Li C, Lin S, Yang Y, Liu D, Han Y, Zhang Y, Li L, Zhou L, Kumar S: Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol; 2006 Jul;37(7):861-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions.
  • Microvessel density (MVD) is regarded as a surrogate marker for angiogenesis and has been used for tumor prognosis.
  • The expression of CD105 in the microvessels within benign lesions was barely visible, and MVD was markedly lower than that determined by CD34.
  • In gastric carcinoma, CD105 expression in microvessels was as high as the MVD, compared with benign lesions.
  • Correlation analysis showed that MVD determined by CD105 correlated with blood vessel invasion, distant metastasis, and formation of ascites.
  • In conclusion, CD34 was universally expressed in blood vessels within benign and malignant tissues, whereas CD105 expression was minimal in benign tissues but stronger in gastric carcinoma.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD34 / biosynthesis. Gastritis / pathology. Neovascularization, Pathologic. Polyps / pathology. Receptors, Cell Surface / biosynthesis. Stomach Neoplasms / blood supply
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunohistochemistry. Male. Microcirculation / metabolism. Microcirculation / pathology. Middle Aged. Prognosis. Stomach Diseases / metabolism. Stomach Diseases / pathology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784986.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


10. Kiessling F, Jugold M, Woenne EC, Brix G: Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging. Eur Radiol; 2007 Aug;17(8):2136-48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging.
  • The switch to an angiogenic phenotype is an important precondition for tumor growth, invasion and spread.
  • Since newly formed vessels are characterized by structural, functional and molecular abnormalities, they offer promising targets for tumor diagnosis and therapy.
  • Previous studies indicate that MRI is valuable to assess vessel morphology and function.
  • It can be used to distinguish between benign and malignant lesions and to improve delineation of proliferating areas within heterogeneous tumors.
  • In addition, tracer kinetic analysis of contrast-enhanced image series allows the estimation of well-defined physiological parameters such as blood volume, blood flow and vessel permeability.
  • Frequently, changes of these parameters during cytostatic, anti-angiogenic and radiation therapy precede tumor volume reduction.
  • This review summarizes strategies for non-invasive characterization of tumor vascularization by functional and molecular MRI, hereby introducing representative preclinical and clinical applications.
  • [MeSH-major] Magnetic Resonance Angiography / methods. Neoplasms / blood supply. Neovascularization, Pathologic / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308924.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 96
  •  go-up   go-down


11. Misawa T, Yoshida K, Iida T, Sakamoto T, Gocho T, Hirohara S, Wakiyama S, Ishida Y, Yanaga K: Minimizing intraoperative bleeding using a vessel-sealing system and splenic hilum hanging maneuver in laparoscopic splenectomy. J Hepatobiliary Pancreat Surg; 2009;16(6):786-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimizing intraoperative bleeding using a vessel-sealing system and splenic hilum hanging maneuver in laparoscopic splenectomy.
  • Recently, the efficacy of Ligasure (a vessel-sealing system) as a safety device for sealing vessels and reducing intraoperative blood loss has been reported with various laparoscopic procedures.
  • We have performed this new LS in 30 consecutive adult patients presenting with idiopathic thrombocytopenic purpura (n = 14), benign splenic tumor (n = 5), lymphoma (n = 4), hereditary spherocytosis (n = 2), liver cirrhosis (n = 2), and other pathologies (n = 3).
  • Mean blood loss for all patients with completed LS was only 21.6 ml (range 0-250 ml).
  • Moreover, blood loss was not determinable (considered as 0 ml in this study) in 15 patients (52%).
  • CONCLUSIONS: LS using a Ligasure in combination with the splenic hilum hanging maneuver may reduce intraoperative blood loss.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Laparoscopy / methods. Spleen / surgery. Splenectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779666.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Lanuti M, De Delva PE, Gaissert HA, Wright CD, Wain JC, Allan JS, Donahue DM, Mathisen DJ: Review of superior vena cava resection in the management of benign disease and pulmonary or mediastinal malignancies. Ann Thorac Surg; 2009 Aug;88(2):392-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of superior vena cava resection in the management of benign disease and pulmonary or mediastinal malignancies.
  • BACKGROUND: Obstruction of the superior vena cava (SVC) by tumor or benign disease implies unreconstructable disease and poor outcome.
  • We analyzed the operative results, graft patency, and survival in patients undergoing SVC resection and reconstruction for benign disease and pulmonary or mediastinal malignancy.
  • METHODS: Patients undergoing SVC resection from 1997 to 2007 for surgical management of benign and invasive neoplasms were retrospectively reviewed.
  • Two patients (10%) with benign processes required reconstruction for chronic SVC syndrome.
  • CONCLUSIONS: Resection and reconstruction may be safely performed in selected patients for benign and malignant obstruction or infiltration of the SVC.
  • [MeSH-minor] Aged. Aged, 80 and over. Blood Vessel Prosthesis Implantation. Female. Humans. Male. Middle Aged. Retrospective Studies. Vascular Patency

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2009 Aug;88(2):397-8 [19632381.001]
  • (PMID = 19632380.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


13. Chang RF, Huang SF, Moon WK, Lee YH, Chen DR: Solid breast masses: neural network analysis of vascular features at three-dimensional power Doppler US for benign or malignant classification. Radiology; 2007 Apr;243(1):56-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid breast masses: neural network analysis of vascular features at three-dimensional power Doppler US for benign or malignant classification.
  • PURPOSE: To retrospectively evaluate the accuracy of neural network analysis of tumor vascular features at three-dimensional (3D) power Doppler ultrasonography (US) for classification of breast tumors as benign or malignant, with histologic findings as the reference standard.
  • Three-dimensional power Doppler US images of 221 solid breast masses (110 benign, 111 malignant) were obtained in 221 women (mean age, 46 years; range, 25-71 years).
  • After narrowing down vessels to skeletons with a 3D thinning algorithm, six vascular feature values--vessel-to-volume ratio, number of vascular trees, total vessel length, longest path length, number of bifurcations, and vessel diameter-were computed.
  • RESULTS: Mean values of vessel-to-volume ratio, number of vascular trees, total vessel length, longest path length, number of bifurcations, and vessel diameter were 0.0089 +/- 0.0073 (standard deviation), 26.41 +/- 14.73, 23.02 cm +/- 19.53, 8.44 cm +/- 10.38, 36.31 +/- 37.06, and 0.088 cm +/- 0.021 in malignant tumors, respectively, and 0.0028 +/- 0.0021, 9.69 +/- 6.75, 5.17 cm +/- 4.78, 1.68 cm +/- 1.79, 6.05 +/- 7.55, and 0.064 cm +/- 0.028 in benign tumors, respectively (P < .001 for all six features).
  • CONCLUSION: Three-dimensional power Doppler US images and neural network analysis of features can aid in classification of breast tumors as benign or malignant.
  • [MeSH-major] Breast / blood supply. Breast Neoplasms / ultrasonography. Imaging, Three-Dimensional / methods. Neural Networks (Computer)
  • [MeSH-minor] Adult. Aged. Blood Vessels / anatomy & histology. Blood Vessels / ultrasonography. Female. Humans. Middle Aged. ROC Curve. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312276.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Marchesini AC, Magrio FA, Berezowski AT, Neto OB, Nogueira AA, Candido dos Reis FJ: A critical analysis of Doppler velocimetry in the differential diagnosis of malignant and benign ovarian masses. J Womens Health (Larchmt); 2008 Jan-Feb;17(1):97-102
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A critical analysis of Doppler velocimetry in the differential diagnosis of malignant and benign ovarian masses.
  • METHODS: An observational study was performed including 67 patients, 15 (22.4%) with malignant ovarian neoplasm and 52 (77.6%) with benign ovarian diseases.
  • Doppler measurements were obtained from each identified vessel, and resistive index (RI), pulsatility index (PI), peak systolic velocity (PSV), and end-diastolic velocity (EDV) were measured.
  • The lower RI value, evaluated in at least two distinct sites of the tumor, was able to improve the performance of gray-scale ultrasound in differential diagnosis of ovarian masses.
  • [MeSH-major] Laser-Doppler Flowmetry. Ovarian Diseases / ultrasonography. Ovary / blood supply
  • [MeSH-minor] Blood Flow Velocity. Diagnosis, Differential. Female. Humans. Neovascularization, Pathologic / ultrasonography. Ovarian Neoplasms / ultrasonography. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240986.001).
  • [ISSN] 1540-9996
  • [Journal-full-title] Journal of women's health (2002)
  • [ISO-abbreviation] J Womens Health (Larchmt)
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Peschos D, Damala C, Stefanou D, Tsanou E, Assimakopoulos D, Vougiouklakis T, Charalabopoulos K, Agnantis NJ: Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol; 2006 06;21(6):603-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions.
  • They are involved in basement membrane disruption, stroma and blood vessel penetration, metastasis and more recently there is evidence that they participate in tumor growth and angiogenic events.
  • With the present study, we tried to demonstrate the expression of MMP-9 immunohistochemically, comparatively in benign, premalignant and malignant lesions of the larynx.
  • The MMP-9 expression was related neither to survival nor to the other available clinicopathological parameters (tumor size, grade, clinical stage, lymph node status and patient age).
  • [MeSH-minor] Carcinoma in Situ / chemistry. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Disease Progression. Female. Humans. Immunohistochemistry. Keratosis / metabolism. Keratosis / pathology. Laryngeal Diseases / metabolism. Laryngeal Diseases / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Papilloma / chemistry. Papilloma / metabolism. Papilloma / pathology. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528670.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


16. Kilic N, Tilki D, Ergün B, Seitz M, Stief CG, Reich O, Ergün S: Epithelial versus endothelial CEACAM1 expression and angiogenesis in epididymal adenomatoid tumor. Anticancer Res; 2010 Jul;30(7):2651-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial versus endothelial CEACAM1 expression and angiogenesis in epididymal adenomatoid tumor.
  • BACKGROUND/AIM: To study the expression of the pro-angiogenic factor carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) in epididymal adeno-matoid tumor tissue, a very rare benign neoplasia, in relation to its vascularization.
  • MATERIALS AND METHODS: Immunohistochemistry for CEACAM1 and for both endothelial markers CD31 and CD34 was performed in normal human epididymal and epididymal adenomatoid tumor tissue.
  • The vessel density was calculated in four tumor regions with different degrees of vascularization in comparison to the vascularization of the normal epididymal tissue.
  • RESULTS: CEACAM1 was found in normal epididymal epithelium, while the epithelium of tumor glands was mostly negative.
  • Only few blood vessels and lymphatics in adenomatoid tumor tissue expressed CEACAM1.
  • The assessment of vascularization revealed either equal or a significantly lower vessel density in some adenomatoid tumor regions in comparison to normal epididymal tissue.
  • DISCUSSION: These data demonstrate that despite its epithelial down-regulation, CEACAM1 is not present in the majority of adenomatoid tumor blood vessels, which might be related to the lower angiogenic activity and benign behaviour of this tumor.
  • [MeSH-major] Adenomatoid Tumor / blood supply. Antigens, CD / biosynthesis. Cell Adhesion Molecules / biosynthesis. Testicular Neoplasms / blood supply
  • [MeSH-minor] Antigens, CD31 / biosynthesis. Antigens, CD34 / biosynthesis. Endothelial Cells / metabolism. Epididymis / blood supply. Epididymis / metabolism. Epithelial Cells / metabolism. Humans. Immunohistochemistry. Male. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682994.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / CD66 antigens; 0 / Cell Adhesion Molecules
  •  go-up   go-down


17. Huang SF, Chang RF, Moon WK, Lee YH, Chen DR, Suri JS: Analysis of tumor vascularity using three-dimensional power Doppler ultrasound images. IEEE Trans Med Imaging; 2008 Mar;27(3):320-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of tumor vascularity using three-dimensional power Doppler ultrasound images.
  • Tumor vascularity is an important factor that has been shown to correlate with tumor malignancy and was demonstrated as a prognostic indicator for a wide range of cancers.
  • Three-dimensional (3-D) power Doppler ultrasound (PDUS) offers a convenient tool for investigators to inspect the signals of blood flow and vascular structures in breast cancer.
  • We extracted the skeleton of blood vessels from 3-D PDUS data to facilitate the capturing of morphological changes.
  • Nine features including vessel-to-volume ratio, number of vascular trees, length of vessels, number of branching, mean of radius, number of cycles, and three tortuosity measures, were extracted from the thinning result.
  • Benign and malignant tumors can therefore be differentiated by a score computed by a multilayered perceptron (MLP) neural network using these features as parameters.
  • The proposed system was tested on 221 breast tumors, including 110 benign and 111 malignant lesions.
  • The results demonstrate a correlation between the morphology of blood vessels and tumor malignancy, indicating that the newly proposed method can retrieves a high accuracy in the classification of benign and malignant breast tumors.
  • [MeSH-major] Algorithms. Image Interpretation, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Neoplasms / blood supply. Neoplasms / ultrasonography. Neovascularization, Pathologic / ultrasonography. Ultrasonography, Doppler / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334428.001).
  • [ISSN] 0278-0062
  • [Journal-full-title] IEEE transactions on medical imaging
  • [ISO-abbreviation] IEEE Trans Med Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Wang Q, Zhang P, Zhang Q, Wang X, Li J, Ma C, Sun W, Zhang L: Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J; 2008 Apr;49(2):192-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of CD137 and CD137L expression in human primary tumor tissues.
  • AIM: To assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity.
  • METHODS: Expression of CD137 and CD137L was assessed by immunohistochemistry in frozen sections of 12 human normal tissues, 15 benign tumors of epithelial or mesenchymal origin (adenoma and leiomyoma), and 36 malignant tumors of epithelial origin (squamous cell carcinoma and adenocarcinoma).
  • The expression of CD137L on 9 human tumor cell lines (3 hepatocarcinoma, 2 lung carcinoma, 2 colon carcinoma, 1 lymphoma, and 1 leukemia) was detected by reverse transcription polymerase chain reaction.
  • To analyze the role of CD137L expressed on tumor cells, we co-cultured tumor cells expressing CD137L with activated T lymphocytes expressing CD137 or with Chinese hamster ovary cells expressing CD137 and then detected by ELISA the levels of cytokines (IL-8, IFN-gamma) secreted by tumor cells or activated T cells.
  • RESULTS: The expression of CD137 and CD137L was observed only in human benign (2/15, 3/15) or malignant tumors (15/36, 21/36), but not in normal tissues (0/12, 0/12).
  • CD137 was expressed on the vessel walls within tumor tissues, whereas CD137L was expressed on tumor cells.
  • Furthermore, CD137L expression found on tumor cell lines was functional because the ligation of CD137L on lung squamous carcinoma cells L78 with CD137 on T cells induced IFN-gamma production by T cells, and ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with CD137 triggered tumor cells to produce IL-8.
  • CONCLUSION: CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors.
  • [MeSH-minor] Cell Line, Tumor. Disease Progression. Humans. Immunohistochemistry. Signal Transduction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9 [10604232.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2903-10 [10946324.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):543-9 [11293902.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1313-24 [11466348.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4897-906 [11994439.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3459-65 [12067989.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3617-27 [12516549.001]
  • [Cites] Cell Immunol. 2003 Nov;226(1):37-44 [14746806.001]
  • [Cites] Transpl Int. 2004 Aug;17(7):351-61 [15349720.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1043-52 [7849293.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3360-7 [7561030.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2488-94 [9498794.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1849-62 [9607925.001]
  • [Cites] Semin Immunol. 1998 Dec;10(6):481-9 [9826581.001]
  • [Cites] J Leukoc Biol. 2005 Mar;77(3):281-6 [15618293.001]
  • [Cites] Annu Rev Immunol. 2005;23:23-68 [15771565.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):449-60 [16113601.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):798-806 [16942440.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2758-67 [17460060.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4910-8 [17878391.001]
  • (PMID = 18461674.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Antigens, CD137
  • [Other-IDs] NLM/ PMC2359873
  •  go-up   go-down


19. Chang RF, Huang SF, Moon WK, Lee YH, Chen DR: Computer algorithm for analysing breast tumor angiogenesis using 3-D power Doppler ultrasound. Ultrasound Med Biol; 2006 Oct;32(10):1499-508
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer algorithm for analysing breast tumor angiogenesis using 3-D power Doppler ultrasound.
  • Angiogenesis provides blood supply for tumor expansion and also increases the opportunity for tumor cells to enter the blood or lymph circulation.
  • Several proangiogenic factors as well as the contribution of the microenvironment to tumor-induced angiogenesis have been identified.
  • Tumor vessels are structurally and functionally abnormal because of an imbalance of these angiogenic regulators.
  • In contrast to normal vessels, tumor vasculature is highly disorganized, tortuous and dilated, with uneven diameter and excessive branching.
  • In other words, the morphologic features are likely to carry additional clues that, when used in conjunction with more established parameters, can improve the present diagnostic approaches.
  • In our study, we present a new method that helps to capture the morphologic features from three-dimensional (3-D) power Doppler ultrasound (PDUS) images.
  • After narrowing down the vessels into their skeletons using a 3-D thinning algorithm, we extracted seven features including vessel-to-volume ratio, number of vascular trees, number of bifurcation, mean of radius and three tortuosity measures, from the skeleton and applied a neural network to classify the tumors by using these features.
  • In investigations into 221 solid breast tumors, including 110 benign and 111 malignant cases, the p values using the Student's t-test for all features were less than 0.05, indicating that the proposed features were deemed statistically significant.
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / blood supply. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / ultrasonography. Female. Humans. Image Processing, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Middle Aged. Neural Networks (Computer). ROC Curve. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045870.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Lin EY, Li JF, Bricard G, Wang W, Deng Y, Sellers R, Porcelli SA, Pollard JW: Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol; 2007 Dec;1(3):288-302
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages.
  • To determine whether vascular endothelial growth factor A (VEGF-A) produced by tumor-associated macrophages regulated the onset of the angiogenic switch, a genetic approach was used to restore expression of VEGF-A into tumors at the benign stages.
  • This stimulated formation of a high-density vessel network and in macrophage-depleted mice, was followed by accelerated tumor progression.
  • The expression of VEGF-A led to a massive infiltration into the tumor of leukocytes that were mostly macrophages.
  • This study suggests that macrophage-produced VEGF regulates malignant progression through stimulating tumor angiogenesis, leukocytic infiltration and tumor cell invasion.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):147-62 [12465600.001]
  • [Cites] J Biol Chem. 1996 Feb 16;271(7):3877-83 [8632007.001]
  • [Cites] J Interferon Cytokine Res. 2005 Nov;25(11):674-83 [16318581.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Development. 2000 Jun;127(11):2269-82 [10804170.001]
  • [Cites] Growth Factors. 1996;13(1-2):57-64 [8962720.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] EMBO J. 2004 Jul 21;23(14):2800-10 [15229650.001]
  • [Cites] Cell. 2006 Jan 13;124(1):175-89 [16413490.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] FASEB J. 2002 Mar;16(3):283-92 [11874978.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):288-302 [18509509.001]
  • [Cites] Lab Invest. 2005 May;85(5):608-23 [15765121.001]
  • [Cites] Circ Res. 2007 Mar 2;100(4):e47-57 [17272806.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):177-89 [12463738.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1155-63 [12393599.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2637-43 [12928417.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 19;86(2):120-6 [8271294.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(5):1477-88 [12588969.001]
  • [Cites] Mol Cell Biol. 1990 Nov;10(11):5822-9 [1700274.001]
  • [Cites] J Leukoc Biol. 1994 Mar;55(3):410-22 [7509844.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4625-9 [8840975.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5064-6 [17545580.001]
  • [Cites] J Virol. 1992 Dec;66(12):7529-32 [1331537.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1779-87 [16931911.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3336-43 [8605350.001]
  • [Cites] Genet Vaccines Ther. 2004 Sep 13;2(1):13 [15363111.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):623-33 [15343380.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7788-95 [8631822.001]
  • [Cites] J Gen Virol. 2001 May;82(Pt 5):1027-41 [11297677.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11238-46 [17114237.001]
  • [Cites] J Exp Med. 2001 Mar 19;193(6):727-40 [11257139.001]
  • [Cites] Nature. 2005 Sep 15;437(7057):417-21 [16163358.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] J Pathol. 2000 Mar;190(4):430-6 [10699991.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • (PMID = 18509509.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100324; United States / NCI NIH HHS / CA / P30 CA 13330; United States / NCI NIH HHS / CA / P01 CA100324-010001; United States / NCI NIH HHS / CA / R01 CA094173-05; United States / NCI NIH HHS / CA / R01 CA094173; United States / NCI NIH HHS / CA / P01 CA100324-019003; United States / NCI NIH HHS / CA / CA RO1 94173; United States / NCI NIH HHS / CA / CA PO1 100324; United States / NCI NIH HHS / CA / P30 CA013330
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse; 147336-22-9 / Green Fluorescent Proteins
  • [Keywords] NOTNLM ; PyMT / VEGF / angiogenesis / macrophages / malignancy / mammary / mouse / progression / transgenic / tumor
  •  go-up   go-down


21. Lederle W, Stark HJ, Skobe M, Fusenig NE, Mueller MM: Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells. Am J Pathol; 2006 Nov;169(5):1767-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells.
  • Platelet-derived growth factor (PDGF) stimulates tumor growth and progression by affecting tumor and stromal cells.
  • In the HaCaT skin carcinogenesis model, transfection of immortal nontumorigenic and PDGF-receptor-negative HaCaT keratinocytes with PDGF-B induced formation of benign tumors.
  • In vivo, persistent PDGF-B expression induced enhanced tumor cell proliferation but only transiently stimulated stromal cell proliferation and angiogenesis.
  • Accordingly, in HaCaT/PDGF-B transplants, initially enhanced VEGF expression by stromal fibroblasts was subsequently reduced, followed by down-regulation of angiogenesis, myofibroblast accumulation, and vessel maturation.
  • The PDGF-induced, persistently increased expression of the hepatocyte growth factor by fibroblasts in vitro and in vivo was most probably responsible for enhanced epithelial cell proliferation and benign tumor formation.
  • Thus, by paracrine stimulation of the stroma, PDGF-BB induced epithelial hyperproliferation, thereby promoting tumorigenicity, whereas the time-limited activation of the stroma followed by stromal maturation provides a possible explanation for the benign tumor phenotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1999 Jun;126(14):3047-55 [10375497.001]
  • [Cites] Cancer Res. 1987 Jul 1;47(13):3425-9 [3034415.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(16):5763-7 [3039506.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • [Cites] Science. 1988 Jun 10;240(4858):1529-31 [2836952.001]
  • [Cites] EMBO J. 1988 Dec 1;7(12):3727-35 [2463166.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2840-7 [2183932.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6130-8 [1698118.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):2021-5 [1848018.001]
  • [Cites] Lab Invest. 1991 Mar;64(3):321-9 [1848332.001]
  • [Cites] Am J Pathol. 1992 Mar;140(3):639-48 [1372158.001]
  • [Cites] Lab Invest. 1992 Oct;67(4):529-34 [1434531.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):393-7 [8380638.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2065-75 [8486774.001]
  • [Cites] Histochem J. 1993 Apr;25(4):251-66 [7684033.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):479-92 [9250160.001]
  • [Cites] Exp Cell Res. 1997 Aug 1;234(2):434-41 [9260914.001]
  • [Cites] Methods Mol Biol. 1997;75:305-11 [9276280.001]
  • [Cites] Nat Med. 1997 Nov;3(11):1222-7 [9359696.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] Development. 1998 May;125(9):1591-8 [9521897.001]
  • [Cites] Histochem Cell Biol. 1998 Apr;109(4):349-57 [9562384.001]
  • [Cites] Exp Cell Res. 1998 Apr 10;240(1):1-6 [9570915.001]
  • [Cites] Circ Res. 1999 Feb 19;84(3):298-305 [10024303.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1294-305 [15735015.001]
  • [Cites] Exp Cell Res. 2005 Jul 15;307(2):292-304 [15950618.001]
  • [Cites] Exp Eye Res. 2006 Jan;82(1):74-80 [16198337.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1896-902 [16322476.001]
  • [Cites] J Clin Invest. 1994 Jan;93(1):131-9 [7506710.001]
  • [Cites] J Cell Biol. 1994 May;125(4):917-28 [7514607.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):42-8 [9096664.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):398-406 [10652433.001]
  • [Cites] Oncogene. 2000 Sep 7;19(38):4337-45 [10980609.001]
  • [Cites] FASEB J. 2001 Feb;15(2):447-57 [11156960.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Bioessays. 2001 Jun;23(6):494-507 [11385629.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12072-7 [11593017.001]
  • [Cites] Lab Invest. 2001 Dec;81(12):1709-16 [11742041.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12456-62 [11799124.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):135-43 [12107098.001]
  • [Cites] Microvasc Res. 2002 Nov;64(3):372-83 [12453432.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):486-97 [12492491.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):533-46 [12547711.001]
  • [Cites] Lab Invest. 2003 Feb;83(2):163-73 [12594232.001]
  • [Cites] Nat Med. 2003 Jun;9(6):685-93 [12778167.001]
  • [Cites] Acta Biochim Pol. 2003;50(3):647-58 [14515146.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] J Cell Biol. 1982 Feb;92(2):584-8 [7061598.001]
  • [Cites] J Clin Invest. 1982 Apr;69(4):1046-9 [7076844.001]
  • [Cites] Cell. 1986 Jul 18;46(2):155-69 [3013421.001]
  • [Cites] N Engl J Med. 1986 Dec 25;315(26):1650-9 [3537791.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1283-316 [10508235.001]
  • (PMID = 17071599.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Endostatins; 0 / Growth Substances; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 0 / platelet-derived growth factor BB; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  • [Other-IDs] NLM/ PMC1780216
  •  go-up   go-down


22. Lokeshwar VB, Cerwinka WH, Isoyama T, Lokeshwar BL: HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res; 2005 Sep 1;65(17):7782-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor.
  • However, it is controversial whether hyaluronidase (e.g., HYAL1) functions as a tumor promoter or as a suppressor.
  • Blocking HYAL1 expression inhibited tumor growth by 4- to 7-fold, whereas high HYAL1 producing transfectants either did not form tumors (DU145) or grew 3.5-fold slower (PC-3 ML).
  • Whereas vector and moderate HYAL1 producers generated muscle and blood vessel infiltrating tumors, HYAL1-AS tumors were benign and contained smaller capillaries.
  • Specimens of high HYAL1 producers were 99% free of tumor cells.
  • This study shows that, depending on the concentration, HYAL1 functions as a tumor promoter and as a suppressor and provides a basis for anti-hyaluronidase and high-hyaluronidase treatments for cancer.
  • [MeSH-minor] Animals. Apoptosis / physiology. Cell Cycle / physiology. Cell Growth Processes / physiology. Cell Line, Tumor. DNA, Antisense / genetics. Humans. Hyaluronic Acid / biosynthesis. Isoenzymes. Male. Mice. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / enzymology. Transfection. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140946.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2R01-CA061038; United States / PHS HHS / / R01 072821-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Antisense; 0 / Isoenzymes; 9004-61-9 / Hyaluronic Acid; EC 3.2.1.35 / Hyaluronoglucosaminidase
  •  go-up   go-down


23. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT: Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer; 2007 Feb 1;109(3):588-97
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.
  • METHODS: Meningioma cell lines (IOMM-Lee, CH157-MN, WHO grade I primary cultured tumor) were transplanted into flanks of nude mice fed mouse chow with celecoxib at varying concentrations (0, 500, 1000, 1500 ppm) ad libitum.
  • RESULTS: Celecoxib reduced growth of mean tumor volume by 66% (P < .05), 25% (P > .05), and 65% (P < .05) compared with untreated controls in IOMM-Lee, CH157-MN, and benign tumors, respectively.
  • Blood vessel density decreased and apoptotic cells increased in treated flank tumors.
  • [MeSH-minor] Animals. Apoptosis. Celecoxib. Cyclooxygenase 2 / metabolism. Factor VIII / metabolism. Humans. Immunoenzyme Techniques. In Situ Nick-End Labeling. Ki-67 Antigen / metabolism. Mice. Mice, Nude. Survival Rate. Tumor Cells, Cultured. Vascular Endothelial Growth Factor A / metabolism. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17177201.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Ki-67 Antigen; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; 9001-27-8 / Factor VIII; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


24. Lazaarev AF, Avbalian AM, Bobrov IP, Klimachev VV, Mischenko EV: [Co-adaptation of enzymatic systems of cells and blood supply in smooth muscle tumors of the corpus uteri]. Vopr Onkol; 2008;54(5):606-10
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Co-adaptation of enzymatic systems of cells and blood supply in smooth muscle tumors of the corpus uteri].
  • We investigated co-adaptation of enzymatic systems of cells using data on activity of NAD(Ph)-dependent enzymes and AgNOR proteins of vascular endothelium vis-a-vis angiogenesis in benign and malignant smooth muscle tumors of the corpus uteri.
  • Overall metabolic activity (NAD-H2 diaphorase) was found to directly correlate with angiogenesis and endothelial vessel proliferation (r = 0.76 and 0.84, respectively).
  • SDH-regulated oxidation in the main metabolic succession of a tricarbonic acid cycle depended on blood supply and endothelial vessel proliferation (r = 0.84 and 0.92, respectively; p = 0.04).
  • A similar relationship was shown for anaerobic glycolysis of SDH (LDH content), on the one hand, and blood supply and endothelial vessel proliferation(r = 0.57 and 0.70, respectively; p = 0.02), on the other.
  • Hence, metabolic profile varied in unaltered myometrium and tumor with variable cellular density and peculiar extracellular matrix.
  • [MeSH-major] Antigens, Nuclear / metabolism. NADP / metabolism. Neovascularization, Pathologic / metabolism. Uterine Neoplasms / blood supply. Uterine Neoplasms / metabolism
  • [MeSH-minor] Adult. Female. Glycolysis. Humans. Middle Aged. Sarcoma / blood supply. Sarcoma / metabolism. Succinate Dehydrogenase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069475.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins; 53-59-8 / NADP; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


25. Scordi-Bello IA, Snyder A, Schwartz M, Fallon JT: Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. Cardiovasc Pathol; 2009 Jul-Aug;18(4):243-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor.
  • Epithelioid hemangioendothelioma is a rare neoplasm of vascular origin with an unknown etiology.
  • Its biologic behavior lies somewhere between that of a benign hemangioma and that of a malignant angiosarcoma; however, it is unpredictable at best.
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Ascites / etiology. Blood Vessel Prosthesis Implantation. Edema / etiology. Humans. Immunohistochemistry. Magnetic Resonance Angiography. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417368.001).
  • [ISSN] 1879-1336
  • [Journal-full-title] Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
  • [ISO-abbreviation] Cardiovasc. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ai Z, Zhang W, Luo W, Huang L, Pan Y: Expression of Pin1 mRNA in non-small-cell lung cancer patients. Asian Cardiovasc Thorac Ann; 2009 Apr;17(2):157-61
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pin1 mRNA expression in blood samples from patients with lung cancer, controls with benign lung disease, and healthy subjects were determined by a real-time reverse transcriptase polymerase chain reaction.
  • Compared to those with benign lung disease and healthy controls, Pin1 mRNA was overexpressed in patients with non-small-cell lung cancer, and the levels correlated with lymph node-positive disease and tumor stage.
  • There was no significant difference in Pin1 expression between groups based on pulmonary vessel ligation.
  • These findings suggest that Pin1 might be a useful tumor marker for cancer therapy.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Peptidylprolyl Isomerase / genetics. RNA, Messenger / blood
  • [MeSH-minor] Aged. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Ligation. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pulmonary Artery / surgery. Pulmonary Surgical Procedures. Pulmonary Veins / surgery. Time Factors. Treatment Outcome. Up-Regulation

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19592546.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NIMA-interacting peptidylprolyl isomerase; 0 / RNA, Messenger; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


27. Grubstein A, Yepes M, Kiszonas R: Magnetic resonance imaging of breast vascularity in medial versus lateral breast cancer. Eur J Radiol; 2010 Aug;75(2):e9-11
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Breasts with malignant tumors can demonstrate a general increased vascularity compared to the contralateral breast and a prominent blood vessel adjacent to the tumor on magnetic resonance imaging (MRI).
  • The aim of the study was to further characterize these alterations in blood supply by location of the tumor within the breast using MRI.
  • Fifty-one had pathologically verified malignant tumors (study group), 11 had pathologically verified benign lesions (control), and 43 had negative scans (control).
  • Origin of the vascular supply and vessel diameter was recorded in a blinded manner.
  • In 4 cases, no dominant vessel was noted.
  • Maximum vessel diameter was 3.6+/-1.1mm in the patients with malignancy and 2.6 +/- 0.8mm in the controls (p<0.0005).
  • General increased vascularity was demonstrated in 91% of the medial tumor subgroup and 83% of the lateral tumor subgroup, as opposed to 36-37% in the control groups (p<0.0005).
  • Follow-up MRI, performed in 8 patients in the malignant-tumor group after treatment, revealed a considerable decrease in the prominent vessels, to a size close to that of the controls.
  • CONCLUSION: Breasts with malignant tumors are characterized by an altered general vascular supply, a prominent feeding vessel, and increased regional vascularity.
  • Both the presence and location of the tumor affect the vascular supply.
  • [MeSH-major] Breast / blood supply. Breast Neoplasms / blood supply. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19926240.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


28. Ozdoğru I, Duran M, Sarli B, Oğuzhan A: Left atrial myxoma supplied by the circumflex coronary artery arising from the right sinus of Valsalva. Turk Kardiyol Dern Ars; 2008 Dec;36(8):549-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myxoma is the most common primary tumor of the heart.
  • Although cardiac myxomas are histologically benign, they may be a source of emboli and cause intracardiac obstruction resulting in acute myocardial infarction.
  • [MeSH-major] Heart Neoplasms / blood supply. Heart Neoplasms / complications. Myxoma / blood supply. Myxoma / complications. Ventricular Dysfunction, Left / etiology
  • [MeSH-minor] Adult. Coronary Angiography. Coronary Vessel Anomalies. Diagnosis, Differential. Echocardiography. Electrocardiography. Heart Atria / surgery. Humans. Male. Neovascularization, Pathologic. Sinus of Valsalva. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223722.001).
  • [ISSN] 1016-5169
  • [Journal-full-title] Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
  • [ISO-abbreviation] Turk Kardiyol Dern Ars
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


29. Tátrai P: [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis]. Magy Onkol; 2008 Dec;52(4):379-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By double immunofluorescent studies, agrin was localized to the muscular layer of blood vessel walls, the BM of bile ducts and ductular reaction, the microvessel walls of HCC, and occasionally the BM of hepatocellular tumor cells.
  • Colocalization, gene expression, and mRNA in situ hybridization experiments suggested that the sources of agrin include vascular smooth muscle cells, epithelial cells of bile ducts and ductules, activated mesenchymal cells in the stroma of hepatocellular tumors, and occasionally tumor hepatocytes.
  • Agrin in the BMs of bile ducts and blood vessels is thought to play an important role in the survival of bile duct epithelium and vascular endothelium, respectively.
  • As opposed to HCC neovessels that were consistently found agrin-positive, normal and cirrhotic sinusoids were always devoid of agrin, raising the possibility that agrin IHC might be useful in the differential diagnosis of benign versus malignant hepatocellular lesions.
  • Agrin IHC was performed on 68 benign lesions (8 large regenerative nodules, 23 low-grade and 7 high-grade dysplastic nodules, 30 liver adenomas) and 29 malignant lesions (8 small HCC, 21 HCC), and was evaluated semi-quantitatively.
  • Based on the results of IHC for agrin as well as CD34, a decision algorithm was devised that differentiated benign and malignant parenchymal lesions with a sensitivity of 93.1% and a specificity of 92.6%.
  • Hence, we propose that agrin IHC might help distinguish between malignant hepatocellular lesions and their benign mimickers.
  • [MeSH-major] Agrin / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / diagnosis. Liver Cirrhosis / diagnosis. Liver Neoplasms / diagnosis. Neovascularization, Pathologic / metabolism

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068466.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Agrin; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Heparan Sulfate Proteoglycans; 0 / RNA, Messenger
  •  go-up   go-down


30. Vincensini D, Dedieu V, Eliat PA, Vincent C, Bailly C, de Certaines J, Joffre F: Magnetic resonance imaging measurements of vascular permeability and extracellular volume fraction of breast tumors by dynamic Gd-DTPA-enhanced relaxometry. Magn Reson Imaging; 2007 Apr;25(3):293-302
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular permeability (k(ep), min(-1)) and extracellular volume fraction (v(e)) are tissue parameters of great interest to characterize malignant tumor lesions.
  • Indeed, it is well known that tumors with high blood supply better respond to therapy than poorly vascularized tumors, and tumors with large extracellular volume tend to be more malignant than tumors showing lower extracellular volume.
  • Furthermore, the transport of therapeutic agents depends on both extracellular volume fraction and vessel permeability.
  • Thus, before treatment, these tissue parameters may prove useful to evaluate tumor aggressiveness and to predict responsiveness to therapy and variations during cytotoxic therapies could allow to assess treatment efficacy and early modified therapy schedules in case of poor responsiveness.
  • In this work, blood-tissue permeability and extracellular volume fraction information were derived from magnetic resonance imaging dynamic longitudinal relaxation rate (R(1)) mapping obtained after an intravenous bolus injection of Gd-DTPA in a group of 92 female patients with breast lesions, 68 of these being histologically proven to be with carcinoma.
  • For the sake of comparison, 24 benign lesions were studied.
  • As a consequence of neoangiogenesis, results showed a higher permeability in malignant than in benign lesions, whereas the extracellular volume fraction value did not allow any discrimination between benign and malignant lesions.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Capillary Permeability. Gadolinium DTPA. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Microcirculation / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17371717.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


31. Teifke A, Behr O, Schmidt M, Victor A, Vomweg TW, Thelen M, Lehr HA: Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology; 2006 May;239(2):351-60
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the association of dynamic enhancement parameters of benign and malignant breast lesions at magnetic resonance (MR) imaging with microvessel distribution and histologic prognostic tumor characteristics.
  • Surgical resection specimens of breast lesions (32 benign, 86 malignant) in 118 patients (age range, 28-86 years; mean, 58 years) who had undergone dynamic T1-weighted MR imaging of both breasts were included in the study.
  • In malignant lesions, TNM stage, tumor grade, proliferative activity, and hormone receptor expression were determined.
  • RESULTS: Malignant lesions exhibited a higher ratio of microvessels in tumor periphery versus tumor center than did benign lesions (P < .0005).
  • High vessel ratios (P = .001) and low central vessel numbers (P = .007) were associated with high tumor grade.
  • Visible rim enhancement was the most accurate prognostic enhancement criterion for estrogen receptor status (P = .007), tumor grade (P = .06), and lymph node status (P = .046).
  • CONCLUSION: The different enhancement behaviors of malignant and benign breast lesions cannot be explained by MVD alone; however, a low MVD in the center of carcinoma is reflected quantitatively by a high enhancement ratio and qualitatively by rim enhancement, with an implication of adverse prognosis.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2006.
  • (PMID = 16569783.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Fernández Vázquez JM, Camacho Galindo J, Mochón Halabe C: [Cutaneous lobular capillary hemangioma of the hand during pregnancy. A case report]. Acta Ortop Mex; 2007 Jan-Feb;21(1):42-4
MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hemangioma lobular capilar cutáneo en mano en el embarazo. Informe de un caso.
  • Hemangiomas are abnormal blood vessel proliferations representing the 4th most common tumor of the hand and are frequent among women in their twenties.
  • They have not been much studied and it is important to know that even though they are benign neoplasias, their course may be aggressive an therefore appropriate treatment is mandatory.

  • Genetic Alliance. consumer health - Hemangioma.
  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695208.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


33. Kajo K, Macháleková K, Pauer M: [Retiform hemangioendotelioma in a 8-year-old girl--case report]. Cesk Patol; 2009 Jul;45(3):72-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RHE belongs to a group of vascular tumors of intermediate malignancy and together with Dabska tumor form a category of so-called hobnail hemangioendotheliomas.
  • Histologically, the tumor consisted of a net of vessel formations with retiform appearance and prominent endothelial nuclei.
  • Other benign and malignant vascular lesions with hobnail cells (hemangioma, angiosarcoma) have to be considered in differential diagnosis.
  • [MeSH-minor] Child. Female. Humans. Lewis Blood-Group System

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764161.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] slo
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Lewis Blood-Group System
  •  go-up   go-down


34. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS: The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer; 2007 Apr 10;96(7):1083-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EphB4 is a member of the largest family of transmembrane receptor tyrosine kinases and plays critical roles in axonal pathfinding and blood vessel maturation.
  • All five malignant ovarian tumour cell lines tested expressed higher levels of EphB4 compared with the two benign cell lines.
  • Treatment of malignant, but not benign, ovarian tumour cell lines with progesterone, but not oestrogen, led to a 90% reduction in EphB4 levels that was associated with 50% reduction in cell survival.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2001 Feb 15;230(2):139-50 [11161568.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):151-6 [17179984.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):220-6 [12562648.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):603-10 [12594815.001]
  • [Cites] Pathol Oncol Res. 2004;10(1):26-33 [15029258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5583-8 [15067119.001]
  • [Cites] Cell. 1998 May 29;93(5):741-53 [9630219.001]
  • [Cites] Virchows Arch. 1998 Aug;433(2):103-11 [9737787.001]
  • [Cites] Mol Cell. 1999 Sep;4(3):403-14 [10518221.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4623-32 [15930280.001]
  • [Cites] BMC Cancer. 2005;5:119 [16171530.001]
  • [Cites] Oncogene. 2006 Feb 2;25(5):769-80 [16205642.001]
  • [Cites] Panminerva Med. 2006 Mar;48(1):13-7 [16633327.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):15-21 [16499955.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):279-93 [16816380.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1236-48 [16615113.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):25-37 [11801721.001]
  • (PMID = 17353927.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / R01 CA079218; United States / NCI NIH HHS / CA / R01CA79218
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Progestins; 0 / RNA, Small Interfering; 4G7DS2Q64Y / Progesterone; EC 2.7.10.1 / Receptor, EphB4; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2360128
  •  go-up   go-down


35. Tami I, Schibli S, Baldi Balmelli S, Bode-Lesniewska B, Hug U, Giovanoli P: [Glomangiomatosis on the hand. A case report]. Handchir Mikrochir Plast Chir; 2009 Feb;41(1):52-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glomus tumours are solitary benign lesions most frequently located subungually on fingers and toes.
  • In the rare case of a glomangiomatosis, the typical glomus cells are found on the altered vessel wall of the angiomatosis.
  • [MeSH-major] Glomus Tumor / surgery. Hand / surgery. Soft Tissue Neoplasms / surgery. Vascular Neoplasms / surgery
  • [MeSH-minor] Amputation. Angiography. Diagnosis, Differential. Fingers / blood supply. Fingers / pathology. Fingers / surgery. Humans. Magnetic Resonance Angiography. Male. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18629761.001).
  • [ISSN] 1439-3980
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Sando N, Oka K, Moriya T, Saito H, Nagakura S, Mori N, Suzuki T, Ueki H, Ohtani H: Osteosarcoma arising in the breast. APMIS; 2006 Jul-Aug;114(7-8):581-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors were diagnosed as a fibroadenoma and a benign phyllodes tumor, respectively.
  • The tumor occupied the entire breast and measured 12x9x8.5 cm.
  • The tumor cells were spindle-shaped and pleomorphic, with large, irregular nuclei and distinct nucleoli.
  • Many tumor cells had characteristics of osteoblastic and chondroblastic elements producing osteoid, osseous, and cartilaginous intracellular substances.
  • Blood and lymph vessel invasion was present.
  • Tumor cells expressed vimentin, osteopontin, vascular endothelial growth factor, CD10, and alkaline phosphatase, but did not express keratin.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16907866.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


37. Alcázar JL, Cabrera C, Galván R, Guerriero S: Three-dimensional power Doppler vascular network assessment of adnexal masses: intraobserver and interobserver agreement analysis. J Ultrasound Med; 2008 Jul;27(7):997-1001
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this study was to assess intraobserver and interobserver agreement for tumor vascular network evaluation as assessed by 3-dimensional (3D) power Doppler sonography for discriminating benign from malignant adnexal masses.
  • Malignancy was considered in the presence of at least 2 of the following: irregular branching, vessel caliber changes, microaneurysms, and vascular lakes.
  • RESULTS: Twenty (51%) tumors were malignant, and 19 (49%) were benign.
  • [MeSH-major] Adnexa Uteri / blood supply. Adnexa Uteri / ultrasonography. Adnexal Diseases / diagnosis. Imaging, Three-Dimensional / methods. Ovarian Neoplasms / blood supply. Ovarian Neoplasms / diagnosis. Ultrasonography, Doppler, Color / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577662.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Li EX, Shi F, Wu YY, Wu Y, Guo JJ, Dong DF: [The relationship between lymphatic metastasis and serum vascular endothelial growth factor C and cyclooxygenase 2 expression in breast cancer]. Zhonghua Yi Xue Za Zhi; 2008 Jan 8;88(2):88-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the relationship among the serum vascular endothelial growth factor C (sVEGF-C), expression of cyclooxygenase 2 (COX-2), and lymph vessel density (LMVD), and to discuss their role in tumor progression and lymphatic metastasis.
  • METHODS: sVEGF-C level was detected by ELISA in 68 pre-operation breast cancer patients, 35 breast benign disease patients, and 12 healthy women.
  • Immunohistochemical method was used to detect the expression of COX-2 and lymphatic vessel endothelial hyaluronidase receptor (LYVE)-1 in the breast cancer tissues and benign disease tissues obtained during operation. RESULTS:.
  • (1) The sVEGF-C level of the pre-operation breast cancer group was (49 +/- 8) pg/ml, significantly higher than those of the begin tumor group [(8 +/- 4) pg/ml, P = 0.045] and the healthy women [(5 +/- 3) pg/ml, P = 0.003]. (2) The COX-2 overexpression positive rate in the breast cancer tissues was 44.1%, significantly higher than that in the begin disease tissues (11.4%, P = 0.002).
  • [MeSH-major] Breast Neoplasms / pathology. Cyclooxygenase 2 / metabolism. Vascular Endothelial Growth Factor C / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18353210.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / LYVE1 protein, human; 0 / Vascular Endothelial Growth Factor C; 0 / Vesicular Transport Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


39. Phillips JM, Narula N, Deane LA, Box GN, Lee HJ, Ornstein DK, McDougall EM, Clayman RV: Histological evaluation of cold versus hot cutting: clinical impact on margin status for laparoscopic partial nephrectomy. J Urol; 2008 Dec;180(6):2348-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A criticism of this approach has been the potential thermal destruction of the cellular architecture at the tumor margin, precluding the ability to accurately determine whether tumor cells are present.
  • We clinically characterized the histological appearance of tumor margins excised with cold scissors, and bipolar and ultrasonic shears.
  • Variables, including margin fragmentation, artifact, extravascular blood clot, parenchymal hemorrhage, capillary congestion and vessel sealing, were assessed and scored on a scale of 0 to 3, that is 0--none, 1-1% to 25%, 2-26% to 50% and 3--greater than 50%.
  • RESULTS: The pathologist was able to confidently identify cells at the margin as being malignant or benign in all cases.
  • Histologically the ultrasonic scalpel demonstrated increased fragmentation and extravascular blood clotting compared with those of the other cutting methods (p <0.025 and <0.026, respectively).
  • CONCLUSIONS: Despite some degree of cellular damage the ability to determine whether cells at the margin were benign or malignant was not affected by using an energy based bipolar or ultrasonic device.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18930271.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. del Cura JL, Elizagaray E, Zabala R, Legórburu A, Grande D: The use of unenhanced Doppler sonography in the evaluation of solid breast lesions. AJR Am J Roentgenol; 2005 Jun;184(6):1788-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objectives of our study were to investigate differences in Doppler sonography features between benign and malignant breast lesions and between malignant lesions with different prognostic factors and to propose diagnostic criteria for Doppler sonography of breast lesions.
  • RESULTS: Color flow was more frequently seen in malignant (237/348 lesions, 68%) than in benign (171/478, 36%) lesions (p < 0.001).
  • Although an overlap in these values between benign and malignant lesions was observed, all but one nodule with an RI of greater than 0.99 (those with null or inverted diastolic flow) or a PI of greater than 4 were malignant.
  • No significant relationship was found between PI, RI, or flow visualization on power Doppler sonography and tumor grade or lymph node involvement in cancers.
  • However, any lesion with a vessel that has an RI value greater than 0.99 or a PI value greater than 4 within it must be considered as probably malignant regardless of any other sonography sign present.
  • Doppler findings are not useful to predict tumor grade or lymph node involvement.
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Breast / blood supply. Breast / pathology. Female. Humans. Middle Aged. Neovascularization, Pathologic. Predictive Value of Tests. Prognosis. Prospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908531.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Fernández-Cruz L, Blanco L, Cosa R, Rendón H: Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg; 2008 May;32(5):904-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some have suggested that a malignant tumor is a contraindication to laparoscopic resection.
  • Aim The aim of this study was to evaluate the feasibility, safety, and long-term outcome of the laparoscopic approach in patients with functioning, nonfunctioning, or overt malignant pancreatic neuroendocrine tumor (PNT).
  • There were 33 patients with functioning tumors: 4 with gastrinomas (mean size 1.2 cm), 1 with a glucagonoma (4 cm), 3 with vipomas (3.2 cm), 2 with carcinoids (5.2 cm), 20 with sporadic insulinomas (1.4 cm), 2 with insulinoma/multiple endocrine neoplasia type 1 (MEN-1) (4.4 cm), and 1 with a malignant insulinoma (13 cm).
  • Sixteen patients had a nonfunctioning tumor (mean size 5 cm).
  • Long-term outcomes were analyzed by tumor recurrence and patient survival.
  • The operative time and blood loss was significantly lower in the Lap En group compared with the other laparoscopic techniques.
  • The group of patients with malignant tumors undergoing Lap SxDP had a longer operating time and greater blood loss compared with the other distal pancreatectomy (Lap DP) techniques.
  • The overall morbidity was significantly higher after Lap SPDP (26.7%) than after Lap SxDP (12.5%) owing to the occurrence of splenic complications in the Lap SPDP group without splenic vessel preservation two of seven (28.5%).
  • Conclusions This series demonstrates that LPS is feasible and safe in benign-appearing and malignant neuroendocrine pancreatic tumors (NEPTs).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264824.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Mentzel T, Schärer L, Kazakov DV, Michal M: Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases. Am J Dermatopathol; 2007 Oct;29(5):443-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatofibrosarcoma protuberans (DFSP) represents a locally aggressive mesenchymal neoplasm of skin and subcutis with characteristic clinicopathologic, immunohistochemical, and molecular findings.
  • In addition to typical cases, morphologic variants such as pigmented, fibrosarcomatous, myofibroblastic, and granular cell DFSP have been described.
  • Tumor size ranged from 1.5 to 12 cm.
  • Histologically, a nodular growth with peripheral diffuse infiltration, as well as a diffusely infiltrating growth of relatively uniform spindled and stellated tumor cells containing slightly enlarged nuclei, was noted.
  • Three cases were entirely myxoid, and in five cases more than 80% of the tumor area showed myxoid stromal changes.
  • Scattered enlarged tumor cells were seen in two cases.
  • Numerous blood vessels with slightly fibrosed vessel walls were seen in seven cases.
  • Immunohistochemically, tumor cells in all cases stained positively for CD34, and in one case each a focal expression of alpha-smooth muscle actin and epithelial membrane antigen (EMA) was noted.
  • In conclusion, myxoid DFSP represents a very rare morphologic variant with characteristic changes that has to be distinguished from benign and malignant myxoid mesenchymal neoplasms as superficial angiomyxoma, superficial acral fibromyxoma, myxoid solitary fibrous tumor, myxoid perineurioma, low-grade myxofibrosarcoma, low-grade fibromyxoid sarcoma, myxoid liposarcoma, and myxoid synovial sarcoma.

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890911.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Collagen Type I; 0 / Mucin-1; 0 / Proto-Oncogene Proteins c-sis; 0 / collagen type I, alpha 1 chain
  •  go-up   go-down


43. Zhao Y, Liu B, Bian J: [Correlation of time-density curve of CT enhancement with angiogenesis in lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Jun 20;10(3):206-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Newborn blood vessel formation correlates closely with active cellular proliferation of tumor.
  • METHODS: Dynamic CT scans were evaluated in 25 patients with lung cancer and 35 patients with pulmonary benign disease who underwent complete resection and did not receive any chemotherapy or radiotherapy prior to operation.
  • RESULTS: The levels of COX-2 (P < 0.05), VEGF (P < 0.05), MVD (P < 0.05) and CT enhancement value (P < 0.01) in lung cancer group were significantly higher than those in plumonary benign tumor group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118647.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


44. Radovanović D, Stevanović D, Pavlović I, Jasarović D, Mitrović N, Ilić I: [Gastrointerstinal stromal tumors of the stomach--case reports]. Med Pregl; 2008 Jul-Aug;61(7-8):409-13
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraoperatively besides the transverse colon cancer, we found intramural gastric tumor.
  • The immunohystochemical analysis of gastric tumor proves benign GIST.
  • The endoscopic ultrasound showed intramural tumor of the anterior gastric wall, with a visible blood vessel bleeding during endoscopy.
  • DISCUSSION: In the cases with inadequate preoperative diagnoses, the level of resection procedure is based on the size of tumor and the presence of necrosis and bleeding inside the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097381.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


45. Guerriero S, Alcazar JL, Ajossa S, Galvan R, Laparte C, García-Manero M, Lopez-Garcia G, Melis GB: Transvaginal color Doppler imaging in the detection of ovarian cancer in a large study population. Int J Gynecol Cancer; 2010 Jul;20(5):781-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An adnexal mass was first studied in grayscale sonography, and any cystic mass in which the echo architecture was not suggestive of benign tumor was categorized as malignant.
  • Second, any solid excrescences or solid portions of the tumor were evaluated with color/power Doppler sonography.
  • A mass was graded malignant if flow was shown within the excrescences or the solid areas and benign if there was no flow or if flow was only peripheral.
  • CONCLUSIONS: The evaluation of vessel distribution by color Doppler sonography in adnexal masses increases the diagnostic accuracy of grayscale sonography in the detection of adnexal malignancies in a large study population.
  • [MeSH-major] Ovarian Neoplasms / ultrasonography. Ovary / blood supply. Ovary / ultrasonography. Ultrasonography, Doppler, Color / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973268.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


46. Forsberg F, Kuruvilla B, Pascua MB, Chaudhari MH, Merton DA, Palazzo JP, Goldberg BB: Comparing contrast-enhanced color flow imaging and pathological measures of breast lesion vascularity. Ultrasound Med Biol; 2008 Sep;34(9):1365-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From the ultrasound images, the number of color pixels before and after contrast administration relative to the total area of the breast mass was calculated as a first-order measure of fractional tumor vascularity.
  • There was a significant increase in flow visualization pre to post Levovist injection (p = 0.001), but no differences were found between the 11 benign and the eight malignant lesions (p > 0.35).
  • The 30-39 microm vessel range contributed most significantly to the MVD relationship (p < 0.001), whereas the MVA was mainly influenced by vessels 20-29 microm (p < 0.004).
  • In conclusion, contrast-enhanced color flow imaging provides a noninvasive measure of breast tumor neovascularity, corresponding mainly to vessels 20-39 microm in diameter, when used in a typical clinical setting.

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 Jan 1;99(1):3-8 [9011572.001]
  • [Cites] BMJ. 1998 Apr 18;316(7139):1236-8 [9553006.001]
  • [Cites] Ultrasound Med Biol. 1995;21(5):635-47 [8525554.001]
  • [Cites] Radiology. 1995 Jul;196(1):123-34 [7784555.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):765-82 [7533829.001]
  • [Cites] BMJ. 1995 Jan 21;310(6973):170 [7833759.001]
  • [Cites] J Ultrasound Med. 1994 May;13(5):357-65 [8015042.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Ultrasound Med Biol. 1990;16(6):553-9 [2238263.001]
  • [Cites] Semin Ultrasound CT MR. 1989 Apr;10(2):171-6 [2697331.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Ultrasound Med. 2004 Feb;23(2):183-95; quiz 196-7 [14992355.001]
  • [Cites] J Ultrasound Med. 2004 Feb;23(2):173-82 [14992354.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(6):527-30 [14658595.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Sep;82(3):319-26 [14499978.001]
  • [Cites] J Ultrasound Med. 2002 Nov;21(11):1227-35 [12418764.001]
  • [Cites] Ultrasound Med Biol. 2002 Jul;28(7):845-51 [12208324.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jul;74(2):121-9 [12186372.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):883-93 [12072542.001]
  • [Cites] Histopathology. 2000 Apr;36(4):306-12 [10759944.001]
  • [Cites] Ultrasonics. 2000 Mar;38(1-8):105-9 [10829638.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Acad Radiol. 2000 Oct;7(10):800-11 [11048878.001]
  • [Cites] Acad Radiol. 2000 Oct;7(10):824-39 [11048880.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1585-9 [11090380.001]
  • [Cites] Eur J Ultrasound. 2000 Dec;12(2):123-30 [11118919.001]
  • [Cites] Ultrasound Med Biol. 2001 Jan;27(1):3-11 [11295265.001]
  • [Cites] Ultrasound Med Biol. 2002 Jan;28(1):19-26 [11879948.001]
  • [Cites] Ultrasound Med Biol. 2002 Apr;28(4):445-51 [12049957.001]
  • [Cites] Radiology. 1999 Nov;213(2):413-22 [10551221.001]
  • [Cites] J Ultrasound Med. 2000 Jan;19(1):55-61 [10625191.001]
  • [Cites] J Ultrasound Med. 2006 Jan;25(1):143-4 [16371568.001]
  • [Cites] J Ultrasound Med. 2005 Apr;24(4):443-50 [15784762.001]
  • [Cites] Eur J Radiol. 2005 Feb;53(2):238-44 [15664287.001]
  • [Cites] Ultrasonics. 1998 Feb;36(1-5):695-701 [9651599.001]
  • [Cites] Radiology. 1996 Mar;198(3):679-86 [8628854.001]
  • (PMID = 18436369.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA048010-10; United States / NCI NIH HHS / CA / R01 CA060854-04; United States / NCI NIH HHS / CA / CA060854-04; United States / NCI NIH HHS / CA / CA48010; United States / NCI NIH HHS / CA / R25 CA048010-10; United States / NCI NIH HHS / CA / R01 CA060854; United States / NCI NIH HHS / CA / R25 CA048010; United States / NCI NIH HHS / CA / CA60854
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Polysaccharides; 127279-08-7 / SHU 508
  • [Other-IDs] NLM/ NIHMS68641; NLM/ PMC2556965
  •  go-up   go-down


47. Frei-Jones M, McKinstry RC, Perry A, Leonard JR, Park TS, Rubin JB: Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. J Neurosurg Pediatr; 2008 Aug;2(2):125-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infantile or capillary hemangioma is the most common vascular tumor of childhood.
  • Although the lesions are considered benign, 10% of affected children develop life-threatening complications (mortality rate 20-80% in this subgroup).
  • Thalidomide may be an ideal therapy for life-threatening hemangiomas because it inhibits new blood vessel formation by antagonizing both the bFGF and VEGF pathways and has a more acceptable toxicity profile than other agents.

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 1982 Mar;69(3):412-22 [7063565.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Jan;28(1):25-9 [17213418.001]
  • [Cites] N Engl J Med. 1992 May 28;326(22):1456-63 [1489383.001]
  • [Cites] Semin Vasc Surg. 1993 Dec;6(4):204-18 [8305975.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Exp Eye Res. 1997 Jun;64(6):971-8 [9301478.001]
  • [Cites] J Pediatr. 1998 Mar;132(3 Pt 1):527-30 [9544915.001]
  • [Cites] N Engl J Med. 1962 Dec 6;267:1184-92 contd [13934699.001]
  • [Cites] N Engl J Med. 1962 Dec 13;267:1238-44 concl [13934700.001]
  • [Cites] Eur J Pediatr Surg. 2005 Feb;15(1):11-6 [15795821.001]
  • [Cites] Med Hypotheses. 2005;64(6):1093-6 [15823691.001]
  • [Cites] Plast Reconstr Surg. 2005 Jul;116(1):200-4 [15988268.001]
  • [Cites] Pathology. 2005 Apr;37(2):149-51 [16028843.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Nov;27(11):573-81 [16282886.001]
  • [Cites] Pediatr Dermatol. 2006 Mar-Apr;23(2):169-74 [16650230.001]
  • [Cites] Eye (Lond). 2006 Oct;20(10):1228-37 [17019424.001]
  • [Cites] Br J Ophthalmol. 2006 Nov;90(11):1344-9 [16854824.001]
  • [Cites] Pediatrics. 2002 Feb;109(2):E37 [11826247.001]
  • [Cites] J Pediatr Surg. 2004 Mar;39(3):400-4 [15017560.001]
  • [Cites] Childs Nerv Syst. 2006 Nov;22(11):1427-31 [16804715.001]
  • [Cites] J Pediatr Surg. 1983 Dec;18(6):894-900 [6663421.001]
  • (PMID = 18671617.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K30 RR022251; United States / NCRR NIH HHS / RR / TL1 RR024995; United States / NCRR NIH HHS / RR / UL1 RR024992; United States / NCRR NIH HHS / RR / UL1 RR024992; United States / NCRR NIH HHS / RR / UL1 RR024992-01; United States / NCATS NIH HHS / TR / UL1 TR000448
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  • [Other-IDs] NLM/ NIHMS101679; NLM/ PMC2737696
  •  go-up   go-down


48. Fujita S, Nagamachi S, Wakamatsu H, Nishii R, Futami S, Tamura S, Matsuzaki Y, Onizuka T, Hatakeyama K, Asada Y: Usefulness of triple-phase thallium-201 SPECT in non-small-cell lung cancer (NSCLC): association with proliferative activity. Ann Nucl Med; 2008 Dec;22(10):833-9
Hazardous Substances Data Bank. THALLOUS CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the influence of tumor blood flow cannot be ignored by the scan at 4 h after the tracer injection.
  • METHODS: A total of 122 patients with lung nodule, 106 of NSCLC and 16 of benign nodule, were given (201)Tl SPECT before the tumor resection.
  • On the each SPECT image, regions of interest (ROIs) were placed over the tumor contour (T) and contra-lateral normal lung tissue (N) area on one transverse view clearly defined lesions, and T/N ratio on the early image (ER), the delayed image (DR), and the super-delayed image (sDR), and retention indexes (RI and sRI) were calculated.
  • The angiogenesis was measured density of positive micro-vessels for CD34 (micro-vessel density, MVD).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19142701.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 7791-12-0 / thallium chloride; AD84R52XLF / Thallium
  •  go-up   go-down


49. Estrada-Chavez G, Vega-Memije ME, Lacy-Niebla RM, Toussaint-Caire S: Scalp metastases of a renal cell carcinoma. Skinmed; 2006 May-Jun;5(3):148-50
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 80-year-old man presented with a localized tumor of the right occipital scalp.
  • The tumor was a 1-cm, bright red-purple, ulcerated, and crusted exophytic nodule on a smooth base (Figure 1).
  • The patient's medical history included a transurethral prostatic resection 3 years earlier and, 1 year later, a right nephrectomy for a 2-kg kidney tumor verbally reported as "benign."
  • The patient also had a 2-year history of untreated high blood pressure.
  • Histopathologically, the excised tissue was an exo-endophytic nodule of a solid form composed of pleomorphic neoplastic cells with abundant clear cytoplasm, surrounded by fibrous collagen septae, blood vessel proliferation, and areas of hemorrhage (Figures 2 and 3).
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Male. Neoplasm Metastasis






Advertisement